Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cell Immunol. 2018 Aug 28;334:38–41. doi: 10.1016/j.cellimm.2018.08.016

Fig. 1. ADA formation after combination therapy of LMB-100 with immune modulating antibodies.

Fig. 1.

BALB/c mice (n=12) were injected (I.V) with LMB-100 (2.5mg/kg) on days 1, 3, 8, 10, 15 and 17 and with immune modulating antibodies (anti-PDL1 (green), anti-PD1 (red), anti-CTLA4 (purple), anti-OX40 (orange) or vehicle (blue)) (5mg/kg I.P) on days 2, 5, 9, 12, 16 and Blood samples were taken on days 0, 7, 14 and 21 and plasma was isolated. A. Mean titer of anti-LMB-100 at each time point. P value indicates significant variance in AUC as shown in C. B. Titer of each mouse at the end of the experiment (week 4). C. AUC for each mouse in each treatment group. D. Onset time of detectable anti-LMB-100 titer for each treatment group.

Study was performed in two separate experiments (n=4 and n=8). Titers of both experiments are shown. Statistical significance was assessed using one-way ANOVA with Dunn’s multiple comparisons test. Error bars show SEM